Table 11. Summary of main international bodies guidance regarding FMT for CDI.

	FMT recommendation
IDSA 2021 [ 31 ]	FMT only for patients with multiple recurrences of CDI who have failed appropriate antibiotic treatments and where appropriate screening of donor and donor faecal specimens has taken place.
ASID 2016	Recommend FMT as a therapeutic option for second or subsequent CDI recurrence if all other therapy options have failed and there are no contraindications.
ESCMID 2021	FMT may be a rescue therapy for patients with refractory severe complicated CDI for whom surgery is not feasible and in-patients with severe complicated CDI who have deteriorated despite CDI antibiotic treatment and for whom surgery is not feasible. However, they feel this is based on weak evidence and should be on a case-by-case basis with a careful risk assessment and MDT discussion.
NICE 2022 [ 70 ]	Recommend FMT as an option for adults who have had two or more previous confirmed CDI episodes.
American Gastroenterology Association (AGA) 2024	Recommends the use of FMT in hospitalized patients with severe or fulminant CDI who have not responded to antibiotics in 2–5 days but should not be considered in those with bowel perforations, obstruction or immunocompromised status.
British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) 2024	Consider FMT for a first recurrence of CDI or as an adjunct to antibiotics in refractory CDI. Offer FMT to all patients with two or more recurrences of CDI. Consider FMT earlier than after the second CDI recurrence for patients with severe, fulminant or complicated CDI who are not responding to antibiotic therapy.